Ascendis Pharma A (ASND) Net Income towards Common Stockholders (2014 - 2026)

Ascendis Pharma A has disclosed Net Income towards Common Stockholders across 13 years of filings, most recently posting $740.4 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $740.4 million, up 643.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $673.2 million (up 1255.6% YoY), and the FY2025 annual result was -$269.6 million, up 33.28% from the prior year.
• Net Income towards Common Stockholders came in at $740.4 million for Q1 2026 at Ascendis Pharma A, up from -$39.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $740.4 million in Q1 2026 to a low of -$211.6 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$39.6 million (2025), against an average of $35.0 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 202.33% in 2023 and surged 643.24% in 2026, its largest moves.
• Ascendis Pharma A's Net Income towards Common Stockholders stood at -$211.6 million in 2022, then surged by 55.07% to -$95.1 million in 2023, then soared by 56.77% to -$41.1 million in 2024, then advanced by 3.58% to -$39.6 million in 2025, then soared by 1967.84% to $740.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $740.4 million (Q1 2026), -$39.6 million (Q4 2025), and -$73.1 million (Q3 2025), per Business Quant data.